Intensive weekly chemotherapy for locally advanced gastric cancer using 5-fluorouracil, cisplatin, epidoxorubicin, 6S-leucovorin, glutathione and filgrastim: a report from the Ital...

per Cascinu, S., Labianca, R., Graziano, F., Pancera, G., Barni, S., Frontini, L., Luporini, G., Cellerino, R., Catalano, G.
Publicat 1998

Gemcitabine plus vinorelbine in elderly or unfit patients with non-small cell lung cancer

per Beretta, G D, Michetti, G, Belometti, M O, Gritti, G, Quadri, A, Poletti, P, Labianca, R
Publicat 2000

Intensive weekly chemotherapy is not effective in advanced pancreatic cancer patients: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)

per Cascinu, S, Frontini, L, Comella, G, Barni, S, Labianca, R, Battelli, N, Casaretti, R, Zonato, S, Pirovano, M, Catalano, G, Cellerino, R
Publicat 1999

A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive trac...

per Cascinu, S, Graziano, F, Barni, S, Labianca, R, Comella, G, Casaretti, R, Frontini, L, Catalano, V, Baldelli, A M, Catalano, G
Publicat 2001

A phase II study of weekly cisplatin, 6S-stereoisomer leucovorin and fluorouracil as first-line chemotherapy for elderly patients with advanced gastric cancer

per Graziano, F, Santini, D, Testa, E, Catalano, V, Beretta, G D, Mosconi, S, Tonini, G, Lai, V, Labianca, R, Cascinu, S
Publicat 2003

Venous thromboembolism is a relevant and underestimated adverse event in cancer patients treated in phase I studies

per Mandalà, M, Grosso, F, Vitalini, C, Corradino, I, Sanfilippo, R, Colombini, S, Clerici, M, Labianca, R, De Pascale, A, Marsoni, S
Publicat 2012

Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil

per Guglielmi, A, Barni, S, Zaniboni, A, Pella, N, Belvedere, O, Beretta, G D, Grossi, F, Frontini, L, Puglisi, F, Labianca, R, Sobrero, A
Publicat 2004

Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients

per Scartozzi, M, Bearzi, I, Mandolesi, A, Giampieri, R, Faloppi, L, Galizia, E, Loupakis, F, Zaniboni, A, Zorzi, F, Biscotti, T, Labianca, R, Falcone, A, Cascinu, S
Publicat 2011

A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR...

per Cascinu, S, Berardi, R, Salvagni, S, Beretta, G D, Catalano, V, Pucci, F, Sobrero, A, Tagliaferri, P, Labianca, R, Scartozzi, M, Crocicchio, F, Mari, E, Ardizzoni, A
Publicat 2008

Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Ne...

per Brandes, Alba A., Tosoni, A., Franceschi, E., Blatt, V., Santoro, A., Faedi, M., Amistà, P., Gardiman, M., Labianca, R., Bianchini, C., Ermani, M., Reni, M.
Publicat 2009

The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?

per Sobrero, A, Grothey, A, Iveson, T, Labianca, R, Yoshino, T, Taieb, J, Maughan, T, Buyse, M, André, T, Meyerhardt, J, Shields, A F, Souglakos, I, Douillard, J -Y, Cervantes, A
Publicat a Ann Oncol (2018)

Schedule-selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a multicentric phase II study.

per Aschele, C., Guglielmi, A., Frassineti, G. L., Milandri, C., Amadori, D., Labianca, R., Vinci, M., Tixi, L., Caroti, C., Ciferri, E., Verdi, E., Rosso, R., Sobrero, A.
Publicat 1998

A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)

per Cascinu, S, Silva, R R, Barni, S, Labianca, R, Frontini, L, Piazza, E, Pancera, G, Giordani, P, Giuliodori, L, Pessi, M A, Fusco, V, Luporini, G, Cellerino, R, Catalano, G
Publicat 1999

High curative resection rate with weekly cisplatin, 5-fluorouracil, epidoxorubicin, 6S-leucovorin, glutathione, and filgastrim in patients with locally advanced, unresectable gastr...

per Cascinu, S, Scartozzi, M, Labianca, R, Catalano, V, Silva, R R, Barni, S, Zaniboni, A, D'Angelo, A, Salvagni, S, Martignoni, G, Beretta, G D, Graziano, F, Berardi, R, Franciosi, V
Publicat 2004

Infusional 5-fluorouracil, cisplatin and mitomycin C in advanced gastric cancer : A low cost effective regimen

per Cascinu, S, Baldelli, A M, Catalano, V, Giordani, P, Beretta, G D, Silva, R R, Gasparini, G, Mari, D, Maisano, R, Salvagni, S, Barni, S, Labianca, R, Frontini, L, Curti, C, Catalano, G
Publicat 2002

5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer

per Sobrero, A, Guglielmi, A, Cirillo, M, Recaldin, E, Frassineti, G L, Aschele, C, Ravaioli, A, Testore, P, Caroti, C, Gallo, L, Pessi, M A, Cortesi, E, Turci, D, Grossi, F, Labianca, R
Publicat 2001

A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD Group

per Bleiberg, H., Decoster, G., de Gramont, A., Rougier, P., Sobrero, A., Benson, A., Chibaudel, B., Douillard, J. Y., Eng, C., Fuchs, C., Fujii, M., Labianca, R., Larsen, A. K., Mitchell, E., Schmoll, H. J., Sprumont, D., Zalcberg, J.
Publicat a Ann Oncol (2017)

Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB–IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial tr...

per Boni, C, Tiseo, M, Boni, L, Baldini, E, Recchia, F, Barone, C, Grossi, F, Germano, D, Matano, E, Marini, G, Labianca, R, Di Costanzo, F, Bagnulo, A, Pennucci, C, Caroti, C, Mencoboni, M, Zanelli, F, Prochilo, T, Cafferata, M A, Ardizzoni, A
Publicat 2012

Duration of Adjuvant Chemotherapy for Stage III Colon Cancer

per Grothey, A., Sobrero, A.F., Shields, A.F., Yoshino, T., Paul, J., Taieb, J., Souglakos, J., Shi, Q., Kerr, R., Labianca, R., Meyerhardt, J.A., Vernerey, D., Yamanaka, T., Boukovinas, I., Meyers, J.P., Renfro, L.A., Niedzwiecki, D., Watanabe, T., Torri, V., Saunders, M., Sargent, D.J., Andre, T., Iveson, T.
Publicat a N Engl J Med (2018)

Survival following early-stage colon cancer: an ACCENT-based comparison of patients versus a matched international general population(†)

per Renfro, L. A., Grothey, A., Kerr, D., Haller, D. G., André, T., Van Cutsem, E., Saltz, L., Labianca, R., Loprinzi, C. L., Alberts, S. R., Schmoll, H., Twelves, C., Yothers, G., Sargent, D. J., Sargent, D.J., Green, E., Grothey, A., Alberts, S.R., Shi, Q., Renfro, L.A., Yothers, G., O'Connell, M.J., Wolmark, N., de Gramont, A., Gray, R., Kerr, D., Haller, D.G., Guthrie, K., Buyse, M., Labianca, R., Seitz, J.F., O'Callaghan, C.J., Francini, G., Catalano, P.J., Blanke, C.D., Andre, T., Goldberg, R.M., Benson, A., Twelves, C., Sirzen, F., Cisar, L., Van Cutsem, E., Saltz, L.
Publicat a Ann Oncol (2015)